129 related articles for article (PubMed ID: 22294742)
21. Delay of postnatal maturation sensitizes the mouse prostate to testosterone-induced pronounced hyperplasia: protective role of estrogen receptor-beta.
Savolainen S; Pakarainen T; Huhtaniemi I; Poutanen M; Mäkelä S
Am J Pathol; 2007 Sep; 171(3):1013-22. PubMed ID: 17640960
[TBL] [Abstract][Full Text] [Related]
22. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
Pickles T; Hamm J; Morris WJ; Schreiber WE; Tyldesley S
BJU Int; 2012 Dec; 110(11 Pt B):E500-7. PubMed ID: 22564197
[TBL] [Abstract][Full Text] [Related]
23. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
24. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
Grossmann M; Zajac JD
Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
[TBL] [Abstract][Full Text] [Related]
25. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
26. Agonists of luteinizing hormone-releasing hormone in prostate cancer.
Rick FG; Block NL; Schally AV
Expert Opin Pharmacother; 2013 Nov; 14(16):2237-47. PubMed ID: 23984804
[TBL] [Abstract][Full Text] [Related]
27. Opposing roles of ERα and ERβ in the genesis and progression of adenocarcinoma in the rat ventral prostate.
Attia DM; Ederveen AG
Prostate; 2012 Jun; 72(9):1013-22. PubMed ID: 22025007
[TBL] [Abstract][Full Text] [Related]
28. Novel ligands balance estrogen receptor β and α agonism for safe and effective suppression of the vasomotor response in the ovariectomized female rat model of menopause.
McGregor C; Sau A; Ruddy SC; Leung D; Webb M; Durst T; Wright JS; Lagace D; Pratt MA
Endocrinology; 2014 Jul; 155(7):2480-91. PubMed ID: 24823389
[TBL] [Abstract][Full Text] [Related]
29. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
[TBL] [Abstract][Full Text] [Related]
30. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
31. Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract.
Cvoro A; Paruthiyil S; Jones JO; Tzagarakis-Foster C; Clegg NJ; Tatomer D; Medina RT; Tagliaferri M; Schaufele F; Scanlan TS; Diamond MI; Cohen I; Leitman DC
Endocrinology; 2007 Feb; 148(2):538-47. PubMed ID: 17095596
[TBL] [Abstract][Full Text] [Related]
32. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management.
Kim HS; Freedland SJ
Curr Opin Support Palliat Care; 2010 Sep; 4(3):147-52. PubMed ID: 20592607
[TBL] [Abstract][Full Text] [Related]
33. Gene expression changes in rat prostate after activation or blocking of the androgen and estrogen receptor.
Nellemann C; Dalgaard M; Holst B; Bonefeld-Jørgensen EC; Vinggaard AM
Mol Cell Endocrinol; 2005 Jun; 237(1-2):25-35. PubMed ID: 15925091
[TBL] [Abstract][Full Text] [Related]
34. Androgen deprivation therapy: past, present and future.
Schröder F; Crawford ED; Axcrona K; Payne H; Keane TE
BJU Int; 2012 Jun; 109 Suppl 6():1-12. PubMed ID: 22672120
[TBL] [Abstract][Full Text] [Related]
35. Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer.
Phillips I; Shah SI; Duong T; Abel P; Langley RE
Oncol Hematol Rev; 2014; 10(1):42-47. PubMed ID: 24932461
[TBL] [Abstract][Full Text] [Related]
36. 4-Nitrophenol induces Leydig cells hyperplasia, which may contribute to the differential modulation of the androgen receptor and estrogen receptor-α and -β expression in male rat testes.
Zhang Y; Piao Y; Li Y; Song M; Tang P; Li C
Toxicol Lett; 2013 Nov; 223(2):228-35. PubMed ID: 24070737
[TBL] [Abstract][Full Text] [Related]
37. Estrogens and mechanisms of prostate cancer progression.
Carruba G
Ann N Y Acad Sci; 2006 Nov; 1089():201-17. PubMed ID: 17261768
[TBL] [Abstract][Full Text] [Related]
38. Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer.
Yu EY; Hancock ML; Aronson W; Flaig T; Belkoff L; Tutrone R; Taylor R; Hardigan PC; Getzenberg RH
Clin Genitourin Cancer; 2020 Dec; 18(6):436-443. PubMed ID: 32321673
[TBL] [Abstract][Full Text] [Related]
39. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
[TBL] [Abstract][Full Text] [Related]
40. Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer.
Thelen P; Wuttke W; Seidlová-Wuttke D
J Steroid Biochem Mol Biol; 2014 Jan; 139():290-3. PubMed ID: 23872207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
